Heron Therapeutics reports FY 2022 net product sales up 25% to $107.7M; net loss narrows to $182M from $220.7M

HERON THERAPEUTICS, INC. /DE/

Annual net product sales $107.7M (+25% YoY); Q4 net product sales $30.0M (+45% YoY).
Net loss for FY 2022: $182.0M ($1.67/share) vs $220.7M ($2.24) in 2021; Q4 net loss $19.9M ($0.17).
ZYNRELEF Q4 net sales $3.9M (+44% QoQ); APONVIE launched March 6, 2023 with CMS pass-through status.
Oncology care franchise net sales $97.5M in 2022 (+17% YoY); FY 2023 guidance $99M-$103M.
Cash and investments $84.9M at Dec 31, 2022, down from $157.6M; operating cash used $146.9M in 2022.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

HERON THERAPEUTICS, INC. /DE/ reported the three and twelve months ended December 31, 2022 results: revenue $30.0 million and $107.7 million, net income $19.9 million, or $0.17 per share, and $182.0 million, or $1.67 per share, EPS $0.17 per share and $1.67 per share.

Period: the three and twelve months ended December 31, 2022
Revenue: $30.0 million and $107.7 million
Net income: $19.9 million, or $0.17 per share, and $182.0 million, or $1.67 per share
EPS: $0.17 per share and $1.67 per share
Result: reported results

Exact text from the filing

Net product sales for the three and twelve months ended December 31, 2022 were $30.0 million and $107.7 million, respectively, compared to $20.7 million and $86.3 million, respectively, for the same periods in 2021.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

HERON THERAPEUTICS, INC. /DE/ reported full-year 2023 results: revenue $99 million to $103 million. Guidance initiated.

Period: full-year 2023
Revenue: $99 million to $103 million
Guidance: initiated
Result: guidance update

Exact text from the filing

Heron currently expects full-year 2023 net product sales for the oncology care franchise of $99 million to $103 million.

View on SEC.gov

Browse all earnings releases →

HERON THERAPEUTICS, INC. /DE/ filing history →

Source: SEC EDGAR

accession 0000950170-23-009489

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.